Vaccine Technology

OUR TECHNOLOGY

Designing Potent Vaccines with

The Power of RET-V's

  • Recombinant Extracellular Transport Vesicles (RET-Vs), also known as Outer Membrane Vesicles, transport payloads of biochemicals such as nucleic acids, toxins, peptides, etc. to modify a target cell’s activity
  • RET-Vs can be engineered to carry precise payloads and attach surface proteins to direct the ETVs to very specific cell types
  • Derived from genetically engineered probiotics as a technology platform for the targeted delivery of vaccines and immuno-therapeutics.
  • By genetically engineering the surface display of receptors and antigens, we can exquisitely target specific diseases, which enable potent protection against a range of strains.
  • These designer vesicles can also be used with a time-release formulation that enables long acting dosing and reduces the number of administrations. You can read more about the cutting-edge research from Cornell University Professors David Putnam and Matthew DeLisa.

Universal Influenza Vaccine

We are the first company to leverage nature’s Extracellular Transport Vesicles to construct a influenza vaccine candidate, VT-105, that provides robust and durable immunity against multiple influenza strains in preclinical studies. Our lead vaccine candidate addresses the need for improved, effective universal influenza vaccines to prevent influenza and other emerging infectious diseases.


Due to the changeable nature of the influenza virus, current commercial vaccines must be made yearly. This results in less potent vaccines which do not adequately address seasonal strain variation or the emergence of new pandemic influenza variants or other infectious diseases. 


Versatope's recombinant Extracellular Transport Vesicles can display proteins of multiple strains of influenza virus on a single nano-vesicle for a more effective and potent vaccine,


Our current influenza vaccine candidate is being scaled up for an investigative new drug (IND) application. You can read more about this vaccine featured on the

Versatope News page.

Share by: